Company intelligence / Profile preview

Pluri-Expertises

Haifa, Haifa, Israelpluriexpertises.com ↗

Ownership: Private
Development stage: Other

Overview

Pluri has advanced multiple proprietary and partnered cell therapies from preclinical through Phase 1–3 clinical trials. Its MAIT platform enables large-scale production of immune cells for off-the-shelf cancer immunotherapy. The company also manufactures for third parties as a CDMO and has established partnerships in regenerative medicine, foodtech, and agtech[1][2][4]. Clinical results include programs targeting muscle regeneration post-surgery, acute radiation syndrome mitigation, and placental insufficiency.

Therapeutic areas: OncologyHematologyWomen's HealthOther
Modalities: Cell therapyInduced pluripotent stem cell derived therapy3D cell expansion technology
Industry: Biotech

Partnerships

Remedy CellKadimastemcultivated meat collaboration with Tnuva and other global food companies

Beyond the preview

Go deeper on Pluri-Expertises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri-Expertises.

Explore the full profile